{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:56:13Z","timestamp":1793051773674,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clml.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:22:12Z","timestamp":1736295732000},"page":"e348-e358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Viral and Fungal Infections Early After HLA-Mismatched Hematopoietic Stem Cell Transplantation Using Low-Dose Antithymocyte Globulin in High-Risk Patients With Hematological Malignancies Not in Remission"],"prefix":"10.1016","volume":"25","author":[{"given":"Makoto","family":"Hirosawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Akao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1905-0668","authenticated-orcid":false,"given":"Junichi","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2025.01.001_bib0001","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1182\/blood.V91.7.2360","article-title":"Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins","volume":"91","author":"Genestier","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.01.001_bib0002","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1182\/blood-2008-01-130146","article-title":"Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro","volume":"111","author":"Feng","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.01.001_bib0003","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3109\/14653249.2012.715243","article-title":"Immune reconstitution after antithymocyte globulin-conditioned hematopoietic cell transplantation","volume":"14","author":"Bosch","year":"2012","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.clml.2025.01.001_bib0004","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)","volume":"98","author":"Bacigalupo","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.01.001_bib0005","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood-2002-12-3629","article-title":"Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen","volume":"102","author":"Mohty","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.01.001_bib0006","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/bmt.2013.191","article-title":"Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial","volume":"49","author":"Wang","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.01.001_bib0007","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12916-019-1393-7","article-title":"Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study","volume":"17","author":"Lin","year":"2019","journal-title":"BMC medicine"},{"issue":"29","key":"10.1016\/j.clml.2025.01.001_bib0008","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.01.001_bib0009","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with antithymocyte globulin versus no antithymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.01.001_bib0010","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbmt.2010.02.027","article-title":"High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder","volume":"16","author":"Podgorny","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2025.01.001_bib0011","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.bbmt.2015.04.012","volume":"21","author":"Ikegame","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.clml.2025.01.001_bib0012","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for Cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.clml.2025.01.001_bib0013","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.01.001_bib0014","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"23","key":"10.1016\/j.clml.2025.01.001_bib0015","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.01.001_bib0016","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2025.01.001_bib0017","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/trf.12390","article-title":"Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors","volume":"53","author":"Furui","year":"2013","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.clml.2025.01.001_bib0018","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbmt.2017.08.029","article-title":"Optimizing antithymocyte globulin dosing for unrelated donor allogeneic hematopoietic cell transplantation based on recipient absolute lymphocyte count","volume":"24","author":"Kennedy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2025.01.001_bib0019","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.01.001_bib0020","doi-asserted-by":"crossref","unstructured":"Fuji S, Einsele H, Kapp M. Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options. Current opinion in infectious diseases. 2017;30(4):372-6. doi: 10.1097\/qco.0000000000000375.","DOI":"10.1097\/QCO.0000000000000375"},{"issue":"8","key":"10.1016\/j.clml.2025.01.001_bib0021","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.clml.2025.01.001_bib0022","doi-asserted-by":"crossref","first-page":"e13977","DOI":"10.1111\/tid.13977","article-title":"Cytomegalovirus in the transplant setting: where are we now and what happens next? A report from the International CMV Symposium 2021","volume":"24","author":"Kotton","year":"2022","journal-title":"Transpl Infects Dis"},{"issue":"5","key":"10.1016\/j.clml.2025.01.001_bib0023","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/infdis\/jiz181","article-title":"Prospective assessment of Cytomegalovirus immunity in high-risk donor-seropositive\/recipient-seronegative liver transplant recipients receiving either preemptive therapy or antiviral prophylaxis","volume":"220","author":"Limaye","year":"2019","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.clml.2025.01.001_bib0024","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV Reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.01.001_bib0025","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"Takenaka","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2025.01.001_bib0026","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.bbmt.2020.07.002","article-title":"Letermovir prophylaxis decreases burden of Cytomegalovirus (CMV) in patients at high risk for CMV disease following hematopoietic cell transplant","volume":"26","author":"Johnsrud","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2025.01.001_bib0027","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jtct.2022.05.020","article-title":"Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality","volume":"28","author":"Liu","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.clml.2025.01.001_bib0028","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.bbmt.2017.08.007","article-title":"Low-dose antithymocyte globulin for graft-versus-host-disease prophylaxis in matched unrelated allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Bryant","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2025.01.001_bib0029","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1080\/10428194.2020.1747067","article-title":"Clinical outcomes with low dose antithymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation","volume":"61","author":"Mountjoy","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2025.01.001_bib0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jtct.2023.01.026","article-title":"Clinical benefit of low-dose antithymocyte globulin-thymoglobulin as graft-versus-host disease prophylaxis in patients receiving allogeneic peripheral blood stem cell transplantation from HLA-identical donors","volume":"29","author":"Takeuchi","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.clml.2025.01.001_bib0031","first-page":"2208","article-title":"Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study","volume":"94","author":"Curtis","year":"1999","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.01.001_bib0032","first-page":"018","article-title":"A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without post-transplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma","volume":"13","author":"Yoshimitsu","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"10.1016\/j.clml.2025.01.001_bib0033","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","author":"Marr","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.01.001_bib0034","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbmt.2014.03.004","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"20","author":"Girmenia","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.01.001_bib0035","doi-asserted-by":"crossref","unstructured":"Biyun L, Yahui H, Yuanfang L, Xifeng G, Dao W. Risk factors for invasive fungal infections after haematopoietic stem cell transplantation: a systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2024;30(5):601-10. doi: 10.1016\/j.cmi.2024.01.005.","DOI":"10.1016\/j.cmi.2024.01.005"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T20:26:11Z","timestamp":1747686371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2152265025000011"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral and Fungal Infections Early After HLA-Mismatched Hematopoietic Stem Cell Transplantation Using Low-Dose Antithymocyte Globulin in High-Risk Patients With Hematological Malignancies Not in Remission","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}